Deciphex is delighted to announce its successful awarding of an SME Instrument Phase 1 grant from the EU. The company’s application was one of only four successful applications from Ireland in the current round. Approximately only 4% of all applications from across Europe were funded.
Horizon 2020 funds high-potential innovation developed by SMEs through the SME instrument. The SME instrument offers Europe's brightest and boldest entrepreneurs the chance to step forward and request funding for breakthrough ideas with the
potential to create entirely new markets or revolutionise existing ones.
Provided with about € 1.6 billion in funding over the period 2018-2020, the SME Instrument will support ground-breaking innovative ideas for products, services or processes that are ready to conquer global markets.
“Being awarded the EU SME Instrument Phase 1 grant is a fantastic validation of our current strategy. The rigorous review process combined with the extremely low success rate provides us with a good
sense of where we stand in our development as a start up.“ said Dr Donal O’Shea, CEO, “The SME Instrument will facilitate us further refine of our strategy and gets us closer to market launch for our product Patholytix”
Deciphex, an Enterprise Ireland High Potential Startup, based in INVENT DCU, Dublin, Ireland, plan to revolutionise pathology through automation of visual examination of tissue. Founded by former Danaher executives Dr Donal O’Shea and Mark Gregson, our mission is to optimise pathology workflows by helping pathologists focus on critical content.return to news
Invent, DCU, Dublin 9, Ireland